SEPTIN9 and carcinoma: It is now evident that the Epi proColon® test, currently available for clinical application in Europe, obtains its diagnostic utility by targeting the very region of the SEPT9 promoter that displays the highest susceptibility to methylation changes in the adenoma-carcinoma sequence.